To compare the effectiveness and safety of adding dipyridamole or aspirin to warfarin among patients with prosthetic heart valves.
embolism. Major bleeding was not consistently defined and 'major' versus 'minor' was not distinguished in all studies.
The validity assessment of the primary studies was limited to studies stating 'random allocation'. No attempt was made to ascertain the method of randomisation or whether the sequence was concealed. The authors state that 'objective methods' were used to assess the development of major clinical outcomes or adverse consequences, and the methods used to ascertain TE were described. However, there were differences between trials in defining 'major bleeding' events, and these are described in the text. A sensitivity analysis comparing double-blind with non-blinded trials was carried out, and it was stated that no differences in any of the outcomes were found. Such analyses, however, are hindered by the relatively small number of trials in the review. Some information is provided about the review process, but agreement between the reviewers was not reported. The authors acknowledge and discuss many of these limitations in the conclusions.
The authors describe in detail the two recent trials of low-dose aspirin, since their conclusions concerning the low risk of a major bleed are based on these studies. They also attempt to provide explanations for the differences between their results and those of earlier reviews.
The authors' conclusions appear reasonable and clinically important with regard to the first two outcomes (reduction in risk of TE and mortality). The magnitude of the increased risk of a major bleed is less clear as the confidence intervals were wider, and of borderline significance (1.03 to 2.18). Heterogeneity between the studies appeared to be greater for this outcome, although it did not reach statistical significance. The authors acknowledge and discuss the lack of power for this outcome.
Implications of the review for practice and research
Practice: The authors state that low-dose aspirin can be safely added to anticoagulation with an acceptable risk of bleeding, and with reduced rates of death and TE expected.
Research: Large well-designed trials with clear methods of defining and measuring the outcome are required to resolve uncertainty concerning the increased risk of a major bleed with low-dose aspirin. 
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